Current Status and Progression of Endocrinotherapy for Prostate Cancer in the View of Translational Medicine

• Main Authors: Li-ya QIAN, Hai-ling MA, Xiao-feng CHEN, Jun XIE
• Format: Article
• Language: English
• Published: Third Party Medicine International Publishing Group Co. Limited 2016-09-01
• Series: Journal of International Translational Medicine
• Subjects: Prostate cancer; Castration treatment; Anti-androgen treatment; Maximal androgen blockade; Intermittent hormonal therapy; Neoadjuvant hormonal therapy; Adjuvant hormonal therapy; Translational medicine
• Online Access: http://www.jitm.hk/EN/abstract/abstract212.shtml

Prostate cancer is a common malignant tumor in urological system. It is also the second leading cause of high morbidity and mortality among men in Western countries. The occurrence and development of prostate cancer is a multi-factor and multi-step process involving changes of numerous genes from the aspect of molecular genetics. In the last decades, translational medicine has discovered that numerous basic research specific to the prevention, diagnosis and treatment of prostate cancer has broaden the application prospect, especially endocrinotherapy, which is of great importance in the treatment of prostate cancer. This study mainly reviewed the mechanism, indications and therapeutic protocols of endocrinotherapy, including castration treatment, anti-androgen treatment, maximal androgen blockade (MAB), intermittent hormonal therapy (IHT), neoadjuvant hormonal therapy (NHT) and adjuvant hormonal therapy (AHT), aiming to provide references for the clinical treatment of prostate cancer.